Pharma and healthcare: sector news on Friday 30 October 2026
Average tone −0.8 (neutral) across 5 companies with relevant coverage, from 106 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| Haleon | −10.0 | 70 | Coverage was dominated by Haleon's third-quarter sales shortfall and a reduced 2026 growth outlook, attributed to poor sales of cold and flu remedies and problems in China, which drove the shares down sharply. |
| GSK | −3.7 | 21 | Coverage centred on mixed third-quarter results, falling vaccine sales and a share price pullback, with Jefferies downgrading and other brokers trimming targets. |
| AstraZeneca | +6.3 | 13 | Coverage was mostly positive, centred on EU approval for Enhertu, successful late-stage trial results for TEZSPIRE and in gastric cancer, and new AI and drug discovery partnerships. |
| Convatec | +9.2 | 1 | The only relevant coverage was a piece on Convatec's shares showing strength on solid demand. |
| Smith & Nephew | −4.7 | 1 | Coverage was built around a single article asking whether Smith & Nephew can turn around its underperforming US implant unit. |
Strongest stories in the sector
- −10.0 Sales miss forces cut, analysts see margin reset
- −10.0 Shares fall on soft seasonal remedy demand
- −10.0 Weak demand and China problems force lower outlook
- −10.0 Biggest one-day share fall since market debut
- −10.0 Large share price drop on index
- −10.0 Shares reach lowest level in a year
- −10.0 Sharp share drop after weaker quarter and lowered growth view
- −10.0 Shares collapse on soft seasonal demand
- −10.0 Heavy share price fall dominates market wrap
- −10.0 Shares tumble after lowered outlook
- −10.0 Shares crash after quarterly update
- −10.0 Quarter missed, guidance lowered, recovery pushed back
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.